11.3 Clinical Toxicology: Alcohols, Acetaminophen, Salicylates, Carbon Monoxide & Drugs of Abuse

11.3 Clinical Toxicology: Alcohols, Acetaminophen, Salicylates, Carbon Monoxide & Drugs of Abuse

[!NOTE] Clinical Chemistry Core Principle: Clinical and forensic toxicology encompasses the detection, identification, and quantitative assessment of drugs, chemical toxins, and metabolic poisons in biological matrices. A rigorous analytical approach—combining rapid screening techniques with definitive mass spectrometric confirmation—is required to distinguish true exposures from cross-reactive interferents. Furthermore, the technologist must master the metabolic transformations of common overdoses (acetaminophen, salicylates, toxic alcohols, and cellular asphyxiants) to interpret nomograms, calculate osmolal and anion gaps, and guide lifesaving antidotal therapy.

---

1. Two-Tiered Drug Testing Strategy: Screening vs. Confirmation

To balance analytical throughput, cost, and legal defensibility, clinical and workplace toxicology adheres strictly to a two-tiered testing strategy:

+-----------------------------------------------------------------------------------------+
|                        Two-Tiered Toxicology Testing Paradigm                           |
+-----------------------------------------------------------------------------------------+
|                                                                                         |
|                     [ Urine / Biological Specimen Received ]                            |
|                                         │                                               |
|                                         ▼                                               |
|    TIER 1: INITIAL SCREENING (Immunoassay)                                              |
|    - Technologies: EMIT, CEDIA, FPIA, KIMS, Lateral Flow Dipsticks                    |
|    - Characteristics: High throughput, rapid turnaround (<15 min), cost-effective      |
|    - Operating Principle: Competitive binding; qualitative cutoff thresholds             |
|    - Vulnerability: Cross-reactivity with structural analogs (FALSE POSITIVES)          |
|                                         │                                               |
|                     ┌───────────────────┴───────────────────┐                           |
|                     ▼                                       ▼                           |
|             [ Negative Result ]                     [ Presumptive Positive ]            |
|             - Reported as Negative                  - Requires Confirmation             |
|             - No further action                                     │                   |
|                                                             ▼                           |
|    TIER 2: CONFIRMATORY TESTING (Mass Spectrometry)                                     |
|    - Technologies: GC-MS, GC-MS/MS, LC-MS/MS                                           |
|    - Characteristics: High sensitivity, absolute molecular specificity                  |
|    - Operating Principle: Chromatographic retention time separation + electron/chemical |
|                           ionization + mass-to-charge (m/z) fragmentation fingerprint   |
|    - Result: Definitive identification; eliminates all false-positive screen artifacts   |
+-----------------------------------------------------------------------------------------+

Tier 1: Initial Screening Immunoassays

• Methodologies: Enzyme Multiplied Immunoassay Technique (EMIT), Cloned Enzyme Donor Immunoassay (CEDIA), Fluorescence Polarization Immunoassay (FPIA), Kinetic Interaction of Microparticles in Solution (KIMS), and lateral flow colloidal gold strip assays.
• Mechanism: Reagents contain an antibody directed against a class of drug (e.g., opiates or amphetamines) and a labeled drug conjugate. Unlabeled drug in the patient's urine competes with labeled drug for limited antibody binding sites.
• Cutoff Concentrations: Immunoassays are calibrated against an administrative threshold (cutoff). Results below the cutoff are reported as negative, even if trace quantities of drug are present.
• Analytical Vulnerabilities: Immunoassays lack absolute chemical specificity. Antibodies recognize generic structural pharmacophores, leading to cross-reactivity with over-the-counter (OTC) medications and prescription drugs (false positives):
  • Amphetamine Immunoassays: Cross-react with pseudoephedrine, ephedrine, phenylephrine, ranitidine, bupropion, labetalol, and trazodone.
  • Opiate Immunoassays: Cross-react with fluoroquinolone antibiotics (levofloxacin, ofloxacin), rifampin, and dietary poppy seeds (which naturally contain trace morphine and codeine).
  • Phencyclidine (PCP) Immunoassays: Cross-react with dextromethorphan, diphenhydramine, venlafaxine, and tramadol.
  • Cannabinoid (THC) Immunoassays: Modern assays have eliminated NSAID interference (ibuprofen), but cross-reactivity can occur with efavirenz or pantoprazole.

Tier 2: Confirmatory Mass Spectrometry (GC-MS and LC-MS/MS)

• Gold Standard Reference Method: When an immunoassay yields a "presumptive positive," clinical laboratories (and all forensic/workplace testing under SAMHSA guidelines) require confirmation using Gas Chromatography-Mass Spectrometry (GC-MS) or Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).
• Analytical Principle: The specimen undergoes liquid-liquid or solid-phase extraction, followed by chromatographic separation where compounds elute at distinct, highly reproducible retention times ($R_t$). As analytes enter the high-vacuum mass spectrometer, they undergo electron ionization (EI) or electrospray ionization (ESI), fracturing the molecular ion into a distinct, reproducible pattern of mass-to-charge ($m/z$) fragments.
• Selected Ion Monitoring (SIM) / Multiple Reaction Monitoring (MRM): The mass spectrometer monitors specific precursor-to-product ion transitions (qualifier and quantifier ions) and their exact stoichiometric abundance ratios. This molecular fragmentation pattern acts as an unmistakable chemical fingerprint, providing 100% analytical specificity, ruling out all false positives, and quantifying the exact drug concentration.

---

2. SAMHSA 5-Panel Workplace Drugs of Abuse & Key Metabolites

The Substance Abuse and Mental Health Services Administration (SAMHSA) mandates testing protocols for federal workplace screening, establishing standard screening and confirmatory cutoffs for five core drug classes:

+-----------------------------------------------------------------------------------------+
|                   SAMHSA 5-Panel Drugs of Abuse & Target Metabolites                    |
+-----------------------------------------------------------------------------------------+
|  Drug Class        │ Primary Active Agent │ Major Target Urinary Metabolite             |
| ───────────────────┼──────────────────────┼──────────────────────────────────────────── |
|  Cannabinoids      │ Δ9-THC               │ 11-nor-Δ9-THC-9-carboxylic acid (THC-COOH)  |
|  Cocaine           │ Cocaine              │ Benzoylecgonine                             |
|  Opiates / Opioids │ Morphine, Codeine    │ Morphine, Codeine; 6-MAM (Heroin specific!) |
|  Amphetamines      │ d-Amphetamine, Meth  │ Amphetamine, Methamphetamine                |
|  Phencyclidine     │ PCP                  │ Phencyclidine (unchanged parent drug)       |
+-----------------------------------------------------------------------------------------+

1. Cannabinoids (THC)

• Metabolism: The primary psychoactive constituent of Cannabis sativa is $\Delta^9$-tetrahydrocannabinol ($\Delta^9$-THC). In the liver, CYP2C9 rapidly oxidizes $\Delta^9$-THC to active 11-hydroxy-THC, which is further oxidized into the inactive terminal metabolite 11-nor-$\Delta^9$-tetrahydrocannabinol-9-carboxylic acid (THC-COOH), excreted in urine as a glucuronide conjugate.
• Pharmacokinetics: THC-COOH is exceptionally lipophilic, sequestering in adipose tissue stores. In naive or infrequent users, urinary detection windows range from 1 to 3 days. In chronic, daily, heavy cannabis users, sustained release from peripheral adipose tissues results in positive urinary screens for 3 to 4 weeks (or longer) following complete cessation.

2. Cocaine

• Mechanism & Metabolism: An alkaloid from Erythroxylum coca that blocks dopamine, norepinephrine, and serotonin reuptake while acting as a local anesthetic. In the liver and blood, native cocaine has a brief half-life (~1 hour) and is rapidly hydrolyzed by carboxylesterases and pseudocholinesterase into Benzoylecgonine (detection window: 2 to 4 days) and ecgonine methyl ester.
• Cocaethylene Marker: When cocaine and ethanol are ingested simultaneously, hepatic carboxylesterases catalyze a unique transesterification, synthesizing cocaethylene. Cocaethylene is equipotent to cocaine in dopamine reuptake blockade, possesses a significantly longer elimination half-life, and produces severe, synergistic cardiotoxicity (myocardial infarction, malignant ventricular arrhythmias).

3. Opiates vs. Synthetic Opioids: The Critical Analytical Blind Spot

[!IMPORTANT] Critical Laboratory Board Trap: Standard commercial urine "Opiate" immunoassay screens are configured with antibodies raised against the natural phenanthrene alkaloid backbone of morphine. They reliably detect natural opiates (morphine, codeine) and cross-react with semi-synthetic derivatives (hydrocodone, hydromorphone, oxycodone [at higher concentrations]). SYNTHETIC OPIOIDS (FENTANYL, METHADONE, BUPRENORPHINE, TRAMADOL, MEPERIDINE) DO NOT CROSS-REACT ON STANDARD OPIATE IMMUNOASSAYS! A patient presenting in acute respiratory arrest from a lethal fentanyl overdose will test completely NEGATIVE on a standard hospital urine drugs-of-abuse panel. Detection requires dedicated, compound-specific immunoassays or comprehensive LC-MS/MS screening.

• 6-Monoacetylmorphine (6-MAM) — Heroin's Pathognomonic Signature:
  • Heroin (diacetylmorphine) is synthesized by acetylation of morphine. Following IV injection, heroin is rapidly deacetylated in the bloodstream ($t_{1/2} \approx 2\text{ to } 3\text{ minutes}$) to 6-monoacetylmorphine (6-MAM), which is then more slowly hydrolyzed ($t_{1/2} \approx 30\text{ minutes}$) to morphine.
  • Forensic Crux: Because 6-MAM is unique to the chemical synthesis of heroin and is never produced during the metabolism of codeine, morphine, or poppy seeds, the presence of 6-MAM in urine (detection window: 2 to 8 hours) is 100% pathognomonic proof of illicit heroin use.

4. Amphetamines and Phencyclidine (PCP)

• Amphetamines: Sympathomimetic amines ($d$-amphetamine, $d$-methamphetamine) that stimulate presynaptic exocytosis of catecholamines. Methamphetamine is partially metabolized by aromatic hydroxylation and $N$-demethylation to amphetamine. Legal workplace testing requires the presence of both methamphetamine and amphetamine ($>100\text{ ng/mL}$) to confirm methamphetamine abuse. MDMA (Ecstasy/Molly) requires specific cross-reacting antibody formulations.
• Phencyclidine (PCP): An arylcyclohexylamine dissociative anesthetic that acts as a non-competitive NMDA receptor antagonist. Clinical features include intense agitation, analgesia, amnesia, and pathognomonic vertical or rotary nystagmus. Unlike other drugs, PCP is excreted primarily unchanged in urine and is detectable for up to 7 to 14 days following massive ingestion due to extensive tissue sequestration.

---

3. Chain of Custody and Specimen Validity Testing

Workplace, forensic, and legally defensible clinical drug testing is governed by procedural rules that are examined as rigorously as the chemistry itself. A result that is analytically perfect is worthless if the specimen's handling cannot be defended.

The Chain of Custody (COC)

A chain of custody is the unbroken, contemporaneously documented record of every person who handled a specimen from the moment of collection to final disposal. On a federal Custody and Control Form (CCF), each transfer records the date, the printed name and signature of the releasing and receiving individuals, and the purpose of the transfer. Between transfers the specimen is held in a sealed, tamper-evident container with a security seal signed and dated by the donor across the cap.

Key procedural requirements:

• The donor observes the sealing and initials the seal; the specimen is never left unattended and unsealed.
• Collection is normally unobserved (in a restricted-water facility with bluing agent in the toilet); directly observed collection is reserved for defined circumstances such as a prior adulterated or substituted result.
• A split specimen (bottle A / bottle B) lets a donor who disputes a positive request testing of bottle B at a second certified laboratory.
• Any break in the chain — an unsigned transfer, a broken seal, a mismatched identifier — renders the result legally unreportable, regardless of the analytical finding.

Specimen Validity Testing (SVT)

Before any drug screen is interpreted, the urine itself is tested to prove it is genuine, undiluted human urine. Substituted, diluted, and adulterated specimens are the three defined failure modes.

Mechanisms worth knowing. Oxidizing adulterants — nitrite, pyridinium chlorochromate (PCC), and peroxide/peroxidase — chemically destroy the analyte in the specimen, and their classic target is THC-COOH, producing a false-negative cannabinoid screen. Glutaraldehyde and surfactants denature the antibody or disrupt the immunoassay reaction itself. Internal dilution (drinking large volumes of water, sometimes with vitamin B-complex to restore urine color) lowers both creatinine and specific gravity without adding a foreign chemical, which is why creatinine and specific gravity must be read together.

[!IMPORTANT] Distinguish the three reportable non-negative validity outcomes: dilute (creatinine 2 – 20 mg/dL with low specific gravity — a real specimen, too watery), substituted (creatinine < 2 mg/dL — not physiologically human urine), and adulterated (an out-of-range pH, an oxidant, or a foreign chemical detected). Only the last two are treated as a refusal to test.

---

4. Clinical Overdoses and Specific Antidotes

+-----------------------------------------------------------------------------------------+
|                        Acetaminophen Metabolism and Hepatotoxicity                      |
+-----------------------------------------------------------------------------------------+
|                                                                                         |
|                          [ ACETAMINOPHEN (APAP) ]                                       |
|                                     │                                                   |
|         ┌───────────────────────────┼───────────────────────────┐                       |
|         ▼                           ▼                           ▼                       |
|  Glucuronidation (Phase II)   Sulfation (Phase II)     CYP2E1 Oxidation (~5-10%)        |
|     (~60% - Non-Toxic)          (~30% - Non-Toxic)              │                       |
|                                                                 ▼                       |
|                                                      [ NAPQI (Highly Toxic) ]           |
|                                                                 │                       |
|                                            ┌────────────────────┴───────────────────┐   |
|                                            ▼                                        ▼   |
|                                    [ GLUTATHIONE (GSH) ]                   [ GSH DEPLETED ]     |
|                                    Mercapturic acid conjugate              Covalent binding to  |
|                                    (Non-Toxic Renal Excretion)             hepatocyte proteins  |
|                                                                            Centrilobular        |
|                                                                            HEPATIC NECROSIS!    |
|                                                                                     ▲   |
|                                   ANTIDOTE: N-Acetylcysteine (NAC) ─────────────────┘   |
|                                   (Replenishes intracellular glutathione)               |
+-----------------------------------------------------------------------------------------+

Acetaminophen (APAP / Paracetamol)

• Normal Metabolism: At therapeutic doses, 90% of acetaminophen undergoes hepatic Phase II conjugation via glucuronidation (~60%) and sulfation (~30%) to form inert, water-soluble metabolites. Approximately 5% is excreted unchanged in urine. A small fraction (~5% to 10%) is metabolized by microsomal CYP2E1 into a highly electrophilic, cytotoxic intermediate: $N$-acetyl-$p$-benzoquinone imine (NAPQI). Under normal physiological conditions, endogenous hepatic glutathione (GSH) instantly coordinates and detoxifies NAPQI, forming non-toxic cysteine and mercapturic acid conjugates.
• Overdose Pathophysiology: In acute toxic overdose ($>150\text{ mg/kg}$ or $>7.5\text{ to } 10\text{ grams}$ in adults), the primary Phase II glucuronidation and sulfation pathways become overwhelmed and saturated. Excess drug is shunted through CYP2E1, generating massive quantities of NAPQI. Once hepatic glutathione stores drop below 30% of baseline, free, un-neutralized NAPQI binds covalently to nucleophilic sulfhydryl groups on hepatocellular mitochondrial proteins. This causes mitochondrial permeability transition, ATP collapse, and catastrophic centrilobular (Zone 3) hepatic necrosis, accompanied by transaminases (AST/ALT) often exceeding 10,000 U/L.
• The Rumack-Matthew Nomogram:
  • Designed strictly for single, acute oral ingestions with known time of ingestion.
  • Timing Constraint: Serum APAP specimens are valid only when drawn between 4 and 24 hours post-ingestion. Blood drawn earlier than 4 hours cannot be plotted because active gastric absorption is still ongoing, yielding non-equilibrated concentrations that misjudge toxicity risk.
  • Treatment Line: The treatment threshold begins at 150 $\mu\text{g/mL}$ (990 $\mu\text{mol/L}$) at exactly 4 hours post-ingestion and declines with a 4-hour half-life ($75\text{ }\mu\text{g/mL}$ at 8 hours; $37.5\text{ }\mu\text{g/mL}$ at 12 hours). If the patient's concentration falls on or above the treatment line, antidotal therapy is urgently indicated.
• Antidote — $N$-Acetylcysteine (NAC / Acetadote): NAC provides cysteine substrate to restore endogenous glutathione reserves, functions directly as an alternate glutathione surrogate binding free NAPQI, and enhances hepatic microvascular blood flow. When administered within 8 hours of acute ingestion, NAC provides virtually 100% protection against lethal hepatotoxicity.

Salicylates (Aspirin / Acetylsalicylic Acid)

• Biphasic Pathophysiology: Aspirin is rapidly deacetylated in the stomach and blood to salicylic acid. Toxic concentrations exert two distinct, simultaneous biochemical insults:
  1. Direct Stimulation of the Medullary Respiratory Center: Salicylate stimulates neurons in the brainstem respiratory center, provoking intense hyperventilation, hyperpnea, and loss of volatile $CO_2$. This produces an early, primary Respiratory Alkalosis.
  2. Uncoupling of Mitochondrial Oxidative Phosphorylation: Salicylate uncouples oxidative phosphorylation by dissipating the inner mitochondrial proton gradient. The cell can no longer synthesize ATP via ATP synthase, forcing reliance on anaerobic glycolysis. This generates excess lactic acid, stimulates lipolysis and beta-oxidation to generate ketoacids, and inhibits Krebs cycle dehydrogenases (accumulating pyruvate and succinate). This produces a late, severe High Anion Gap Metabolic Acidosis.
  • Classic Presentation: The pathognomonic hallmark of adult salicylate toxicity is a Mixed Acid-Base Disorder: Primary Respiratory Alkalosis combined with High Anion Gap Metabolic Acidosis (arterial blood gas reveals low $pCO_2$, low $HCO_3^-$, with near-normal or low pH).
• Laboratory Measurement: The historical Trinder reaction. Salicylate reacts with ferric nitrate ($Fe^{3+}$) in an acidic solution to form a deep blue-purple iron-phenolate coordination complex, quantified spectrophotometrically at 540 nm.
• Antidotal Treatment — Urinary Alkalinization: Salicylic acid is a weak acid ($pK_a = 3.0$). Administration of intravenous Sodium Bicarbonate ($NaHCO_3$) alkalinizes systemic blood and raises urine pH to $>7.5\text{ to } 8.0$. In alkaline tubular urine, salicylic acid dissociates into negatively charged salicylate anions ($A^-$). Lipid-insoluble charged ions cannot cross renal tubular lipid bilayers back into blood (ion trapping), multiplying renal excretion by 10- to 20-fold.

---

5. Toxic Alcohols: Osmolal Gap vs. Anion Gap

Ingestion of toxic alcohols—methanol, ethylene glycol, and isopropanol—represents a critical medical emergency. The clinical laboratory differential diagnosis relies on calculating both the Osmolal Gap and the Anion Gap:

$\text{Osmolal Gap} = \text{Measured Serum Osmolality (Freezing Point)} - \text{Calculated Osmolality}$

$\text{Calculated Osmolality (mOsm/kg)} = 2 \times [Na^+] + \frac{\text{Glucose [mg/dL]}}{18} + \frac{\text{BUN [mg/dL]}}{2.8}$

(Reference Osmolal Gap: $<10\text{ mOsm/kg}$). Volatile alcohols, being small un-ionized molecules present in high millimolar concentrations, elevate the freezing point-measured osmolality without contributing to calculated osmolality, producing a massive osmolal gap ($>10\text{ to } 50+\text{ mOsm/kg}$). As the alcohol is metabolized by alcohol dehydrogenase (ADH) into organic acids, the osmolal gap progressively diminishes while the High Anion Gap Metabolic Acidosis ($[Na^+] - ([Cl^-] + [HCO_3^-])$) expands.

+-----------------------------------------------------------------------------------------+
|                        Metabolic Cascades of the Toxic Alcohols                         |
+-----------------------------------------------------------------------------------------+
|                                                                                         |
|  METHANOL (Windshield washer fluid, bootleg liquor)                                     |
|    └──> ADH ───> Formaldehyde ───> ALDH ───> FORMIC ACID                                |
|         - Pathology: Optic papillitis, "snowstorm" blindness, putaminal necrosis       |
|         - Lab Profile: High Osmolal Gap + High Anion Gap Acidosis                       |
|         - Antidote: Fomepizole (4-methylpyrazole) or Ethanol                            |
|                                                                                         |
|  ETHYLENE GLYCOL (Antifreeze, hydraulic fluid)                                          |
|    └──> ADH ───> Glycolaldehyde ───> Glycolic Acid ───> OXALIC ACID                    |
|         - Pathology: Calcium oxalate monohydrate crystal deposition in renal tubules;   |
|                      Acute tubular necrosis / anuric renal failure; hypocalcemia        |
|         - Lab Profile: High Osmolal Gap + High Anion Gap Acidosis; urine fluorescence   |
|         - Antidote: Fomepizole or Ethanol                                               |
|                                                                                         |
|  ISOPROPANOL (Rubbing alcohol)                                                          |
|    └──> ADH ───> ACETONE                                                                |
|         - Pathology: CNS depression, gastritis, fruity acetone breath                   |
|         - Lab Profile: High Osmolal Gap + KETOSIS WITHOUT ACIDOSIS!                      |
|                        (Normal Anion Gap, Normal Bicarbonate, Positive Serum Ketones)   |
|         - Antidote: Supportive care only (Fomepizole is NOT indicated)                  |
+-----------------------------------------------------------------------------------------+

1. Ethanol

• Metabolized by hepatic Alcohol Dehydrogenase (ADH) to acetaldehyde, then by aldehyde dehydrogenase (ALDH) to acetate. At legal intoxication levels ($>80\text{ mg/dL}$ or $0.08%\text{ w/v}$), ADH is fully saturated, and clearance follows zero-order kinetics at a fixed rate of 15 to 20 mg/dL/hour in non-tolerant individuals.
• Laboratory Measurement: Enzymatic assay utilizing ADH. Ethanol + $NAD^+ \xrightarrow{\text{ADH}}$ Acetaldehyde + $NADH + H^+$. The rate of absorbance increase at 340 nm is directly proportional to ethanol concentration.
• Pre-Analytical Specimen Protocol: Venipuncture site must be cleansed with an alcohol-free antiseptic (e.g., aqueous benzalkonium chloride or povidone-iodine); NEVER USE ISOPROPANOL ALCOHOL PREP PADS, which can falsely elevate measured alcohol levels.

2. Methanol

• Sources: Windshield washer fluid, model airplane fuel, industrial solvents, bootleg distilled spirits.
• Toxicity: Metabolized by ADH to formaldehyde, then rapidly converted by ALDH into Formic Acid (Formate). Formate inhibits mitochondrial cytochrome c oxidase, causing profound histotoxic hypoxia, high anion gap metabolic acidosis, and selective necrosis of the retinal ganglion cells and optic disc (optic papillitis, producing pathognomonic "snowstorm" blindness), accompanied by bilateral hemorrhagic necrosis of the putamen in the basal ganglia.
• Antidotal Therapy: Fomepizole (4-methylpyrazole / 4-MP), a potent competitive inhibitor of ADH, or IV ethanol (which exhibits a 20-fold higher affinity for ADH than methanol, preventing toxic metabolite generation), followed by hemodialysis.

3. Ethylene Glycol

• Sources: Automotive engine antifreeze, coolant, de-icers.
• Toxicity: Metabolized by ADH to glycolaldehyde $\rightarrow$ glycolic acid (the primary driver of profound high anion gap metabolic acidosis) $ ightarrow$ glyoxylic acid $ ightarrow$ Oxalic Acid (Oxalate). Oxalate chelates systemic calcium ions, precipitating in renal proximal tubules as calcium oxalate monohydrate crystals (characteristic dumbbell, needle, or hemp-seed shapes), causing acute tubular necrosis and acute oliguric renal failure. Concurrently, calcium chelation produces acute hypocalcemia (tetany).
• Diagnostic Clues: Urine examination reveals abundant calcium oxalate monohydrate crystals; urine fluoresces under a Wood's lamp (UV light) due to sodium fluorescein added to commercial antifreeze formulations.
• Antidote: Fomepizole or ethanol, along with IV pyridoxine and thiamine (shunts glyoxylate to non-toxic glycine). Hemodialysis clears parent drug and glycolic acid.

4. Isopropanol (Rubbing Alcohol)

• Toxicity: Metabolized by ADH directly into Acetone. Acetone is a ketone, not an organic acid. Acetone produces CNS depression, lethargy, coma, and hemorrhagic gastritis.
• High-Yield Laboratory Presentation: SEVERE KETOSIS WITHOUT METABOLIC ACIDOSIS. Patients exhibit a strongly positive nitroprusside serum/urine ketone test (detecting acetone/acetoacetate) and a massively elevated osmolal gap, but maintain a completely normal arterial blood gas pH, normal serum bicarbonate, and normal anion gap. Fomepizole is not indicated because acetone does not produce retinal or renal injury.

---

6. Cellular Asphyxiants: Carbon Monoxide and Cyanide

+-----------------------------------------------------------------------------------------+
|                        Cellular Asphyxiants: CO vs. Cyanide                             |
+-----------------------------------------------------------------------------------------+
|  Feature          │ Carbon Monoxide (CO)             │ Cyanide (CN-)                    |
| ──────────────────┼──────────────────────────────────┼───────────────────────────────── |
|  Mechanism        │ Binds Fe2+ in Hemoglobin (250x O2)│ Binds Fe3+ in Cytochrome c Oxidase|
|                   │ Shifts O2 curve LEFT (Haldane)   │ Inhibits electron transport chain|
|  Blood Color      │ Classic "Cherry-Red" blood       │ Bright red venous blood (high SvO2)|
|  Pulse Oximetry   │ FALSELY NORMAL (SpO2 99-100%)    │ Normal SpO2                      |
|  Diagnostic Assay │ Multi-wavelength Co-Oximetry     │ Whole blood cyanide; Lactic acid |
|  Specific Antidote│ 100% O2 / Hyperbaric Oxygen (HBO)│ Hydroxocobalamin (Cyanokit)      |
+-----------------------------------------------------------------------------------------+

Carbon Monoxide (CO)

• Mechanism: Carbon monoxide binds to the ferrous ($Fe^{2+}$) heme iron of hemoglobin with an affinity approximately 200 to 250 times greater than oxygen, forming Carboxyhemoglobin (COHb). Furthermore, CO binding induces an allosteric conformational shift that dramatically shifts the oxyhemoglobin dissociation curve to the left, locking remaining oxygen molecules onto hemoglobin and severely impeding oxygen unloading to ischemic tissues.
• Analytical Crux: Standard two-wavelength pulse oximetry ($SpO_2$) is FALSELY NORMAL (reading 98% to 100%)! Conventional pulse oximeters measure light absorption at only 660 nm and 940 nm and cannot distinguish oxyhemoglobin from carboxyhemoglobin. Definitive diagnosis requires multi-wavelength Co-Oximetry performed on a blood gas analyzer (measuring light absorption at 4 to 8 distinct wavelengths to directly quantify %COHb).
• Reference Thresholds: Normal non-smokers: $<2%$; urban dwellers/smokers: 4% to 9%; severe toxicity: $>15%\text{ to } 20%$ (headache, dyspnea, confusion); lethal: $>50%$.
• Antidote: High-flow 100% normobaric oxygen (shortens COHb half-life from 320 minutes on room air down to 80 minutes) or Hyperbaric Oxygen (HBO at 2.5 to 3.0 atm) (shortens half-life to 20 minutes).

Cyanide ($CN^-$)

• Mechanism: Inhaled during structure fires (burning plastics/wool) or industrial exposures. Cyanide binds with avid affinity to the ferric ($Fe^{3+}$) iron of mitochondrial Cytochrome c Oxidase (Complex IV), completely halting the mitochondrial electron transport chain. Cellular oxidative phosphorylation ceases immediately, blocking aerobic ATP synthesis.
• Hallmark Biochemical Profile: Catastrophic Lactic Acidosis ($>8\text{ to } 10\text{ mmol/L}$) and elevated central venous oxygen saturation ($S_vO_2 > 90%$) with bright cherry-red venous blood, because poisoned tissues are completely incapable of extracting oxygen delivered by circulating arterial hemoglobin.
• Specific Antidote — Hydroxocobalamin (Cyanokit): Hydroxocobalamin enters cells and binds cyanide with high affinity, exchanging its hydroxyl group to form non-toxic cyanocobalamin (Vitamin $B_{12}$), which is safely eliminated in urine. Alternatively, the traditional cyanide antidote kit utilizes sodium nitrite (induces methemoglobinemia, whose $Fe^{3+}$ pulls cyanide away from mitochondria) followed by sodium thiosulfate (substrate for rhodanese to convert cyanide to thiocyanate).

---

7. Heavy Metal Toxicology

• Lead ($Pb$):
  • Mechanism: Binds sulfhydryl groups, inactivating two crucial enzymes in the heme biosynthesis pathway: $\delta$-aminolevulinic acid dehydratase ($\delta$-ALAD) and Ferrochelatase. Inactivation of ferrochelatase prevents insertion of $Fe^{2+}$ into protoporphyrin IX, resulting in the incorporation of zinc to form Zinc Protoporphyrin (ZPP).
  • Laboratory Findings: Elevated whole blood lead, elevated ZPP/free erythrocyte protoporphyrin, and peripheral blood smear demonstrating microcytic hypochromic anemia with basophilic stippling (aggregates of degraded ribosomal RNA due to lead inhibition of pyrimidine 5'-nucleotidase).
  • Specimen Collection: Whole blood collected in a lead-free tan-top tube (K2-EDTA) or royal blue-top tube.
• Arsenic ($As$): Binds sulfhydryl groups and substitutes for inorganic phosphate, inhibiting pyruvate dehydrogenase. Garlic-scented breath, hyperkeratosis, Mees lines on nails. Best assessed via 24-hour urine collection because arsenic clears rapidly from blood.
• Mercury ($Hg$): Exists in elemental, inorganic, and organic (methylmercury from apex predator fish) states. Inactivates sulfhydryl-containing proteins, producing tremor, erethism (behavioral instability), and acrodynia. Assessed via whole blood (organic) and 24-hour urine (inorganic).

Comprehensive Clinical Toxicology Antidote & Diagnostic Summary